The Quantellect read.As of Nov 19, 2026, 5 active firms cover Phathom Pharmaceuticals Inc: 4 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $10.00 to $26.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $18.80 sits 254% above the current $5.31. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.01 next quarter toward $0.90 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy480%
Neutral120%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$18.80
+254.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $5.31 current
Highest Target$26.00
Average Target$18.80
Lowest Target$10.00
Detailed analyst forecasts for PHAT
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate PHAT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PHAT EPS & revenue forecast
EPS · NEXT QUARTER
$0.01
Range $-0.03 – $0.03 · 4 analysts · -103% YoY
Next period, 4 analysts expect Phathom Pharmaceuticals Inc to earn $0.01 a share (range $-0.03 – $0.03), versus $-0.18 a year earlier. Full-year consensus is $-0.04, growing to $0.90 the year after.
REVENUE · NEXT QUARTER
$94.0M
Range $85.0M – $101.0M · 4 analysts · +61% YoY
Revenue is expected to reach $94.0M (range $85.0M – $101.0M), +61.2% year-over-year. Full-year consensus is $315.0M, rising to $488.0M next year.
Top analysts covering Phathom Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PHAT.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
$15.00+182.5% to target
Overall win rate
61%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #84
Buy
$22.00+314.3% to target
Overall win rate
50%
+ Follow
#3
Paul Choi
Goldman Sachs · Rank #110
Neutral
No targeton PHAT
Overall win rate
52%
+ Follow
#4
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$26.00+389.6% to target
Overall win rate
49%
+ Follow
#5
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
No targeton PHAT
Overall win rate
38%
+ Follow
PHAT stock forecast FAQ
What is PHAT's average 12-month price target?+
The 5 active firms with a live target average $18.80 for Phathom Pharmaceuticals Inc over the next 12 months, ranging from a $26.00 high to a $10.00 low, as of Nov 19, 2026.
Is PHAT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PHAT?+
The Street-high target is $26.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Leerink Partners). The average of all 5 active-firm targets is $18.80.
How many active Wall Street firms cover PHAT?+
5 active firms have a recognized rating on Phathom Pharmaceuticals Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PHAT?+
Among analysts who currently cover PHAT, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy with a $15.00 target.
What is Phathom Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.01 per share (range $-0.03 – $0.03) across 4 analysts. Full-year EPS is projected at $-0.04, rising to $0.90 the following year.
How much revenue is Phathom Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $94.0M (range $85.0M – $101.0M). Full-year revenue is projected at $315.0M, growing to $488.0M next year.
Have analysts been upgrading or downgrading PHAT lately?+
As of Nov 19, 2026, 4 of 5 active firms rate PHAT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PHAT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.